Literature DB >> 18805455

Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness.

Inga Velicko1, Luise Ledet Müller, Richard Pebody, Bernadette Gergonne, Chinara Aidyralieva, Nina Kostiuchenko, John S Spika.   

Abstract

The WHO European Region has a measles elimination target for 2010. Between September 2005 and mid-June 2006, more than 50,000 measles cases were reported in Ukraine; many reportedly had received two doses of measles vaccine and over 60% were among persons 15-29 years old. To investigate vaccine effectiveness (VE), a case-control study was undertaken in Dnepropetrovsk region. VE for two doses of measles vaccine was 93.1%, providing insufficient population immunity for measles elimination. An additional dose of measles vaccine for these age-cohorts is required if Ukraine is to achieve measles elimination. Other republics of the former Soviet Union also need to consider a supplemental dose of measles vaccine for older age groups identified epidemiologically to be at increased risk for measles even though individuals may have already received two doses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805455     DOI: 10.1016/j.vaccine.2008.09.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  An assessment of measles vaccine effectiveness, Australia, 2006-2012.

Authors:  Alexis Pillsbury; Helen Quinn
Journal:  Western Pac Surveill Response J       Date:  2015-07-09

2.  Measles epidemic from 1951 to 2012 and vaccine effectiveness in Guangzhou, southern China.

Authors:  Zhicong Yang; Jianxiong Xu; Ming Wang; Biao Di; Huifeng Tan; Qing He; Yanshan Cai; Jianhua Liang; Wensui Hu; Zhiqiang Dong; Yunqing Yang; Chuanxi Fu
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

3.  Outbreak of measles among persons with secondary vaccine failure, China, 2018.

Authors:  Zhujiazi Zhang; Meng Chen; Rui Ma; Jingbin Pan; Luodan Suo; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

4.  Relaxation of purifying selection on live attenuated vaccine strains of the family Paramyxoviridae.

Authors:  Austin L Hughes
Journal:  Vaccine       Date:  2009-02-03       Impact factor: 3.641

5.  Spread of measles virus D4-Hamburg, Europe, 2008-2011.

Authors:  Annette Mankertz; Zefira Mihneva; Hermann Gold; Sigrid Baumgarte; Armin Baillot; Rudolph Helble; Hedwig Roggendorf; Golubinka Bosevska; Jasminka Nedeljkovic; Agata Makowka; Veronik Hutse; Heidemarie Holzmann; Stefan W Aberle; Samuel Cordey; Gheorghe Necula; Andreas Mentis; Gulay Korukluoğlu; Michael Carr; Kevin E Brown; Judith M Hübschen; Claude P Muller; Mick N Mulders; Sabine Santibanez
Journal:  Emerg Infect Dis       Date:  2011-08       Impact factor: 6.883

Review 6.  Evolving measles status and immunization policy development in six European countries.

Authors:  Ivo Vojtek; Heidi Larson; Stanley Plotkin; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2022-02-18       Impact factor: 4.526

7.  Etiology of maculopapular rash in measles and rubella suspected patients from Belarus.

Authors:  Marina A Yermalovich; Galina V Semeiko; Elena O Samoilovich; Ekaterina Y Svirchevskaya; Claude P Muller; Judith M Hübschen
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

Review 8.  Vaccination in elite athletes.

Authors:  Barbara C Gärtner; Tim Meyer
Journal:  Sports Med       Date:  2014-10       Impact factor: 11.136

Review 9.  The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review.

Authors:  Stephanie L Hughes; Shelly Bolotin; Sumaiya Khan; Ye Li; Caitlin Johnson; Lindsay Friedman; Andrea C Tricco; Susan J M Hahné; Jane M Heffernan; Alya Dabbagh; David N Durrheim; Walter A Orenstein; William J Moss; Mark Jit; Natasha S Crowcroft
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

10.  Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.

Authors:  Zhifang Wang; Rui Yan; Hanqing He; Qian Li; Guohua Chen; Shengxu Yang; Enfu Chen
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.